TABLE 3.
Population characteristics of the patients in the olanzapine cohort of the NUSM’s CDW database; quantifiable data are given as means ± SEM.
| With vitamin D | Without vitamin D | p-value | |
|---|---|---|---|
| Patients | 23 | 406 | NA |
| Age (years) | 57.1 ± 4.3 | 48.5 ± 0.9 | 0.06 |
| Female | 18 (78.3%) | 249 (61.3%) | 0.12 |
| Schizophrenia | 5 (21.7%) | 110 (27.1%) | 0.81 |
| Antipsychotics | 12 (52.2%) | 225 (55.4%) | 0.83 |
| Blood glucose (mg/dL) | 103.2 ± 4.7 | 107.6 ± 1.4 | 0.38 |
| HbA1c (%) | 5.55 ± 0.10 | 5.46 ± 0.04 | 0.39 |
| Triglyceride (mg/dL) | 135.2 ± 12.5 | 120.8 ± 4.6 | 0.29 |
| LDL cholesterol (mg/dL) | 125.5 ± 9.1 | 113.1 ± 2.9 | 0.21 |
| HDL cholesterol (mg/dL) | 52.9 ± 5.1 | 55.1 ± 1.0 | 0.67 |
| BMI | Not available | Not available | NA |
| Waist circumference (cm) | Not available | Not available | NA |